San Diego, United States
858 Therapeutics is a biotechnology and drug discovery company focusing on developing small molecule drugs that target novel therapeutic approaches in cancer treatment. Founded in 2019, the company's mission is to address the challenge of drug-resistant cancers through innovative therapeutics. Its team, with a successful track record in pharma and biotech drug discovery, specializes in epigenetics, single cell genomics, and innate immunity.
Headquartered in the biotech hub of San Diego, CA, with laboratory operations in San Diego and New York City, 858 Therapeutics strategically positions itself for accessing leading investigators and scientific talent on both coasts of the US. The company recently received a significant $60.00M Series A investment on 21 September 2021, from prominent investors including New Enterprise Associates, Versant Ventures, Cormorant Asset Management, and Logos Capital.
858 Therapeutics' dedication to pioneering small molecule therapeutics for challenging cancers reflects its potential to make a substantial impact in the biotechnology, healthcare, and pharmaceutical industries.
